Pharmaceutical Stocks

Pharmaceutical stocks have grown tremendously as medicine advances. With diseases like Covid-19, diabetes, liver disease and other illnesses affecting more and more of the population, pharmaceutical companies are racing to find cures – further advancing medicine and driving pharma stock prices higher.

Big Pharma corporations like AstraZeneca, Merck & Co., Pfizer, and Johnson & Johnson are leading the charge against the novel coronavirus, competing with smaller biotech names — such as Moderna and Novavax. The race to find a Covid-19 vaccine has sent both pharma and biotech stocks to the moon.

Johnson & Johnson, Forest Labs Will Make You Sick

By Peter Cohan, InvestorPlace Writer
Johnson & Johnson beat expectations but its profits were down; Forest Labs missed and has a plunging profit forecast. Investors should be wary of both pharma options.

Pfizer Crafting a Post-Patent Game Plan

By Barry Cohen, Health Care Writer
As its Lipitor patent nears expiration, Pfizer considers new uses for Lyrica, its popular painkiller for fibromyalgia.

Should You Buy the Dow — Johnson & Johnson

By Lawrence Meyers, InvestorPlace Contributor
Johnson & Johnson is protected by a diverse product line and sitting on a heap of cash. But JNJ stock already is on the high side of valuation, making this a tough pick.

7 Pharma Stocks to Sell, STAT

By Louis Navellier, Editor, Growth Investor
Pharmaceutical stocks are theoretically recession-proof. Still, not all pharma companies are equal. Here are seven clear losers to toss.

10 Big Pharma Stocks to Buy

By Louis Navellier, Editor, Growth Investor
Pharmaceutical stocks and drugmakers are theoretically recession-proof businesses. Still, not all pharma companies are created equal. Here are 10 clear winners

Lilly Should Survive Patent Loss on Blockbuster Drug Zyprexa

By Barry Cohen, Health Care Writer
On Oct. 23, Eli Lilly will wave goodbye to the U.S. patent on the best-selling drug in its 135-year history. Here's why investors shouldn't be worried.

Bristol-Myers Shares Are a Blue-Chip Keeper

By Deborah OMalley, InvestorPlace Writer
The pharmaceutical giant's stock has posted several new highs and offers an attractive dividend yield.

Onyx’s Staying Power Tied to New Cancer Drug Carfilzomib

By Barry Cohen, Health Care Writer
Onyx needs the financial boost from its multiple myeloma-treating drug to ween it off dependence on an uneasy partnership with Bayer.

Suit Asks J&J CEO to Return Part of 2010 Pay

By Barry Cohen, Health Care Writer
J&J CEO Bill Weldon’s gains don’t reflect shareholder pain, some stakeholders say.

Study Results Boost Analyst’s Forecast for Novartis Drug

By Barry Cohen, Health Care Writer
An analyst boosts his forecast for Novartis' Afinitor based on its promise as a treatment for breast cancer.

FDA’s Easing on Obesity Drugs Could Fatten Investor Wallets

By Barry Cohen, Health Care Writer
Vivus and Orexigen's diet-pill hopes are resurrected as the FDA relaxes its stance against obesity treatments.

9 Healthy Biotech Buys

By Louis Navellier, Editor, Growth Investor
Baby boomers are getting older and in need of more and more treatments, thus the race for the next big blockbuster drug. Smaller biotechs are cashing in.

Shortage of Cancer Drugs Jeopardizes Development of New Treatments

By Barry Cohen, Health Care Writer
Existing products often are used in new drugs' clinical trials, meaning a cramp in supply can result in delays of even years for new treatments.

The Sweet Taste of Swiss Pharma

By Bryan Perry
Drug-maker Roche Holding Ltd. (RHHBY) could win big from the Swiss franc's pegging to the euro.

Regeneron Shares Get a Spark

By Barry Cohen, Health Care Writer
A decision by the VA has lifted prospects for the company's key drug -- and its stock.

Give Bristol-Myers the Benefit Over Merck

By Peter Cohan, InvestorPlace Writer
Bristol-Myers’ robust new drug portfolio could make it an acquisition target -- and an investing target for you -- but neither stock is a bargain.

Fair or Not, Patent Overhaul Bill Looks Like a Win for Big Pharma

By Barry Cohen, Health Care Writer
'First-inventor-to-file' system is a victory for Big Pharma and its investors, but a crushing blow to small companies.

Glaxo Alters R&D Process to Ensure Survival in Changing Pharma Industry

By Barry Cohen, Health Care Writer
GSK has created a "dragon" culture in its R&D process. Here's what it is and why analysts like the Glaxo approach.

AstraZeneca Rolls the Dice on Cholesterol Drug and Comes Up Short

By Barry Cohen, Health Care Writer
Once the patent for Pfizer's popular Lipitor runs out, cheap knockoffs could start eating away at Crestor sales
Load More